{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:16:56Z","timestamp":1778645816281,"version":"3.51.4"},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We retrospectively reviewed 72 anemic patients with myelofibrosis (MF; median age 68\u2009years), who were JAK2 inhibitor\u2010na\u00efve at the time of study entry to a phase\u20101\/2 momelotinib clinical trial. Driver mutation profile included <jats:italic>JAK2<\/jats:italic> 69%, <jats:italic>CALR<\/jats:italic> 17%, <jats:italic>MPL<\/jats:italic> 8%, and triple\u2010negative 6%; other mutations included <jats:italic>ASXL1<\/jats:italic> 39% and <jats:italic>SRSF2<\/jats:italic> 17%. Momelotinib was administered at a median dose of 300\u2009mg daily. Anemia response was assessed by formal criteria and documented in 44% of all patients with hemoglobin levels below the sex\u2010adjusted reference range (<jats:italic>n\u2009=<\/jats:italic>\u00a072), 48% of those with hemoglobin &lt;10\u00a0g\/dl (<jats:italic>n\u2009=<\/jats:italic>\u00a054), and 46% of those who were transfusion\u2010dependent at the time of study entry (<jats:italic>n\u2009=<\/jats:italic>\u00a028). Anemia response was more likely with post\u2010essential thrombocythemia MF (83% vs 37%; <jats:italic>p<\/jats:italic>\u00a0=\u00a0.001), lower serum ferritin (<jats:italic>p<\/jats:italic>\u00a0=\u00a0.003), and shorter time from diagnosis to momelotinib therapy (<jats:italic>p<\/jats:italic>\u00a0=\u2009.001); the first two variables were also predictive in transfusion\u2010dependent patients. Post\u2010momelotinib median survival was 3.2\u2009years; in univariate analysis, survival was superior in anemia responders (median 3.8 vs. 2.8\u2009years; <jats:italic>p<\/jats:italic>\u00a0=\u00a0.14) and in the presence of type 1\/like <jats:italic>CALR<\/jats:italic> mutation and inferior in the presence of age\u2009&gt;\u200965\u2009years, <jats:italic>ASXL1\/SRSF2<\/jats:italic> mutation, unfavorable karyotype, DIPSS\u2010plus high risk, red cell transfusion need and higher serum ferritin. Multivariable analysis confirmed the favorable impact of anemia response on survival (<jats:italic>p<\/jats:italic>\u00a0=\u00a0.02; HR 0.5, 3\/5\/10\u2010year survival; 69%\/38%\/25%). This survival advantage was also noted in transfusion\u2010dependent patients (3.7 vs. 1.9\u2009years; <jats:italic>p<\/jats:italic>\u00a0=\u00a0.01; HR 0.3) and appeared to be restricted to patients with an unfavorable genetic profile. The current study suggests a short\u2010term survival benefit associated with anemia response in momelotinib\u2010treated patients with MF.<\/jats:p>","DOI":"10.1002\/ajh.26778","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T07:18:32Z","timestamp":1667978312000},"page":"282-289","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival"],"prefix":"10.1002","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"first","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2730-8593","authenticated-orcid":false,"given":"Kebede H.","family":"Begna","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-3715","authenticated-orcid":false,"given":"Aref","family":"Al\u2010Kali","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Hogan","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark","family":"Litzow","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9084-4148","authenticated-orcid":false,"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.50"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-740092"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.71"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.330"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002662"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7002"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4418"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30237-5"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01637-7"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2446"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24978"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-588426"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-488098"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26050"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.08.022"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0028-x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9867"},{"issue":"1","key":"e_1_2_9_20_1","first-page":"abstr 628","article-title":"Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis","volume":"140","author":"Oh ST","year":"2022","journal-title":"Blood"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30027-3"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.306"},{"issue":"1","key":"e_1_2_9_23_1","first-page":"abstr 627","article-title":"Updated results from the Momentum phase 3 study of Momelotinib (MMB) versus Danazol (DAN) in symptomatic and anemic Myelofibrosis (MF) patients previously treated with a JAK inhibitor","volume":"140","author":"Gerds AT","year":"2022","journal-title":"Blood"},{"key":"e_1_2_9_24_1","article-title":"Safety and efficacy of Jaktinib in the treatment of Janus kinase inhibitor\u2010Na\u00efve patients with Myelofibrosis: results of a phase II trial","author":"Zhang Y","journal-title":"Am J Hematol"},{"key":"e_1_2_9_25_1","article-title":"Jaktinib (JAK1\/2 inhibitor): a momelotinib derivative with similar activity and optimized dosing schedule","author":"Tefferi A","journal-title":"Am J Hematol"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23406"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0067-6"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1109555"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26778","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.26778","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T11:50:19Z","timestamp":1692532219000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.26778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1002\/ajh.26778"],"URL":"https:\/\/doi.org\/10.1002\/ajh.26778","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,15]]},"assertion":[{"value":"2022-11-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}